89BIO INC. news, videos and press releases
For more news please use our advanced search feature.
89BIO INC. - More news...
89BIO INC. - More news...
- 89bio to Participate in the Leerink Partners Global Healthcare Conference
- 89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- 89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- 89bio Provides Business Update and Outlook for 2025
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio to Participate in the 7th Annual Evercore HealthCONx Conference
- 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
- 89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- 89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
- 89bio to Participate in the UBS Global Healthcare Conference
- 89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
- 89bio to Participate in Upcoming Investor Conferences
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Appoints Francis Sarena as Chief Operating Officer
- 89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
- 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
- 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
